Olema Pharmaceuticals announced its plans to commence a public offering, subject to market and other conditions, to issue and sell shares of its common stock, or for certain investors that so choose, in lieu of shares of common stock, pre-funded warrants to purchase shares of its common stock. All of the securities are being offered by Olema. TD Cowen is acting as book-running manager for the proposed offering.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Pharmaceuticals Terminates ATM Prospectus
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Positive Outlook for Olema’s OPERA-02 Study Following Roche’s Successful Phase 3 Trial Results
- Positive Outlook on Olema Pharmaceuticals’ Palazestrant Driven by Promising Trial Data and Market Potential
- Olema Oncology price target raised to $36 from $28 at H.C. Wainwright